Impact Factor 3.161 | CiteScore 3.13
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Psychiatry | doi: 10.3389/fpsyt.2019.00771

VORTIOXETINE FOR COGNITIVE ENHANCEMENT IN MAJOR DEPRESSION: FROM ANIMAL MODELS TO CLINICAL RESEARCH

  • 1University of Franche-Comté, France

Objectives: Vortioxetine, has already shown its efficacy in the acute and long-term treatment of MDD, and its interest in the prevention of relapse. The aim of this study was to review the current status of knowledge regarding cognitive effects of vortioxetine.
Methods: We conducted a review of key data obtained from preclinical behavioral models and clinical trials in MDD focusing on vortioxetine-induced cognitive changes.
Results: In animal, acute and chronic administration of vortioxetine improved performance on objective measures that cover a broad range of cognitive domains. In human, vortioxetine appears as a useful treatment option in patients with MDD, especially in the presence of cognitive dysfunction.
Conclusion: Vortioxetine constitutes a promising treatment for treatment of cognitive impairment in MDD, but its place in the therapeutic armamentarium still need to be determined.

Keywords: Major depressive diorders, Vortioxetine, Cognition, human, animal

Received: 30 Mar 2019; Accepted: 25 Sep 2019.

Copyright: © 2019 Bennabi, Haffen and Van Waes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Djamila Bennabi, University of Franche-Comté, Besançon, France, dbennabi@chu-besancon.fr